IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0114008.html
   My bibliography  Save this article

Efficacy and Safety of Crizotinib among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients

Author

Listed:
  • Yabing Cao
  • Guangli Xiao
  • Xibin Qiu
  • Sheng Ye
  • Tongyu Lin

Abstract

Introduction: We report the efficacy and safety of crizotinib treatment among Chinese patients with advanced-stage NSCLC. Methods: We retrospectively analyzed patients with EML4-ALK positive advanced NSCLC who were treated with crizotinib from May 2012 to Aug 2013. Baseline clinical parameters, treatment protocol, response to therapy and survival were noted. The primary goal was to evaluate the efficacy of crizotinib in patients who were previously treated patients or who had poor ECOG performance status (PS). Results: Forty patients were evaluable for safety and efficacy. Median age was 43 years, 100% had adenocarcinoma and stage IV disease, and 42.5% were female. Six patients received frontline treatment with crizotinib, 17 patients had 1 prior treatment, and 17 patients had more than 2 lines of prior treatment. Patients received a median of 5 cycles of treatment (range 1–15 cycles). After the first cycle, 92.5% (37/40) patients archived partial remission (PR). At the end of the follow-up period, the overall PR rate was 70% (28/40), and progression of disease (PD) occurred in 30% of patients (12/40). The median PFS was 28 weeks (95% CI 15.4 to 40.5 weeks), and median OS was 40 weeks (95% CI 38.6 to 49.3 weeks). The most frequent treatment-related AEs were vomiting (47.5%), vision disorder (27.5%) and increased ALT/AST (42%); most toxicities were Grade 1/2. Observed treatment-related Grade 3/4 AEs included increased ALT/AST (10%) and vomiting (5%). The EML4-ALK fusion rate and number of prior chemotherapy cycles did not appear to significantly affect the efficacy of crizotinib. However, PS 0–2 patients had improved PFS (50 weeks vs. 24 weeks, p = 0.015). Conclusions: Crizotinib was safe, well-tolerated, and effective in Chinese patients with pre-treated ALK-rearranged NSCLC. QOL was improved and PS appears to have an effect on the efficacy of crizotinib, but prior treatment and ALK fusion rate do not.

Suggested Citation

  • Yabing Cao & Guangli Xiao & Xibin Qiu & Sheng Ye & Tongyu Lin, 2014. "Efficacy and Safety of Crizotinib among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients," PLOS ONE, Public Library of Science, vol. 9(12), pages 1-7, December.
    • Handle: RePEc:plo:pone00:0114008
    DOI: 10.1371/journal.pone.0114008
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0114008
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0114008&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0114008?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Manabu Soda & Young Lim Choi & Munehiro Enomoto & Shuji Takada & Yoshihiro Yamashita & Shunpei Ishikawa & Shin-ichiro Fujiwara & Hideki Watanabe & Kentaro Kurashina & Hisashi Hatanaka & Masashi Bando , 2007. "Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer," Nature, Nature, vol. 448(7153), pages 561-566, August.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Toshiyuki Ishii & Shunichiro Iwasawa & Ryota Kurimoto & Akemi Maeda & Yuichi Takiguchi & Makoto Kaneda, 2015. "Crizotinib-Induced Abnormal Signal Processing in the Retina," PLOS ONE, Public Library of Science, vol. 10(8), pages 1-13, August.
    2. Huiyong Sun & Youyong Li & Sheng Tian & Junmei Wang & Tingjun Hou, 2014. "P-loop Conformation Governed Crizotinib Resistance in G2032R-Mutated ROS1 Tyrosine Kinase: Clues from Free Energy Landscape," PLOS Computational Biology, Public Library of Science, vol. 10(7), pages 1-13, July.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0114008. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.